Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | DRD3 | P35462 | 4/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | HTR1D | P28221 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR1B | P28222 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476394 | 0.80 | CXCR2 (0.42) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL6280229 | 0.80 | TP53 (0.41) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL6101688 | 0.77 | PGR (0.46) | CA1CA2PDK2 | |
| SCHEMBL1091438 | 0.75 | PGR (0.45) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL19844018 | 0.75 | LMNA (0.44) | CHRM1TP53PDK2 | |
| SCHEMBL1952664 | 0.74 | HSD11B1 (0.40) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL6102848 | 0.73 | CA12 (0.46) | CA1 | |
| SCHEMBL1807301 | 0.73 | DRD2 (0.39) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL10440165 | 0.72 | HSD11B1 (0.41) | HSD11B1CHRM1DRD2DRD3DRD4 | |
| SCHEMBL17393794 | 0.72 | HSD11B1 (0.41) | HSD11B1CHRM1DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | HSD11B1 1945/4885CHRM1 3991/4885DRD2 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.